Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/biology-definition/si) was not found.

Search biology definition si at Google

Search biology definition si at Yahoo

Search biology definition si at Msn

Google
 
(Date:12/4/2009)... amyloids the fibrous protein deposits associated with diseases such ... potential new area for therapeutics. , It was believed that ... known as fibres - are inert, but that there may ... and cause disease. , But in a paper published ...
(Date:12/3/2009)... co-workers discovered that specific types of human papillomavirus (HPV) ... pathogens cause cells to degenerate. It is known today ... E7. Both proteins switch off different cellular control functions, ... Rsl and his co-workers at DKFZ have now discovered ...
(Date:12/3/2009)... likened to emptying a museum of its collection, or dumping ... replacing every local cuisine with McDonald,s burgers. , But the ... the world boring. New research now suggests it may also ... , "Habitat destruction and biodiversity loss,"driven by the replacement of ...
Breaking Biology News(10 mins):New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 1Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 2Statement of Support 3A Strengthening Oral Health Care is Key Part of Health Reform 62018 1Statement of Support 3A Strengthening Oral Health Care is Key Part of Health Reform 62018 2Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 1Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 2Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 3
(Date:12/6/2009)... treatments targeting growth factor, researchers say , , SUNDAY, ... cancer cells from the main tumor to other parts ... known as TGFb, which may prove a promising target ... researchers say. , Previous studies have shown that TGFb ... movement. In this new study, a team from Cancer ...
(Date:12/6/2009)... Dec. 6 Blood clotting, or coagulation, ... when a blood vessel is injured. Sometimes, however, ... an obvious injury or do not dissolve naturally, ... today at the 51st Annual Meeting of the ... of using the anticoagulants aspirin and heparin with ...
(Date:12/5/2009)... a phase 1/2 clinical trial that it is ... newly diagnosed with multiple myeloma, a cancer of white ... Cancer Institute. , Partial responses or better were seen ... drug combination in the multi-center study, with 74 percent ... phase 2 population, reports Paul G. Richardson, MD, of ...
(Date:12/5/2009)... NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative ... Research presented today at the 51st Annual Meeting ... new treatment options and improved diagnostic methods for ... leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that ...
(Date:12/5/2009)... MAMA campaign is a collaborative effort by the ... Alliance of North America (MANA), Citizens for Midwifery ... American Registry of Midwives (NARM), and the Midwifery ... recent the efforts of The MAMA Campaign to ...
Breaking Medicine News(10 mins):Health News:Breast Cancer's Spread Now Better Understood 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4
...
... Cell Lines stably express the regulatory ... line is functionally tested for induction ... expression control vector pGene/V5-His/lacZ and by ... with mifepristone (Figure 1). These cell ...
... Kit Includes: Sufficient library for ... x 10^9 independent sequences, -28 gIII ... DNA sequencing, -96 gIII Sequencing Primer ... Host E. coli strain ER2738, Control ...
... Materials for 15-20 enhancements when ... Western Blot Signal Enhancement System is designed to ... is an excellent tool for evaluating proteins with low ... to pre-treat membrane prior to blocking the membrane; 1x ...
Biology Products:
... Nicolet VersaLab is a ... Doppler system for evaluation ... Crisp, clear Doppler sound ... a display and print-out ...
Scoliosis Devices....
... VIASYS Neurocare - continues the ... diagnosis. Exceptional convenience and speed. Superior ... ,VasoGuard delivers features you won't find ... for cuff attachment and testing. Up ...
... The Socon Spinal System is ... components with multiple mounting options. Minimal ... for spondylolisthesis. Solid clamping concept. Monosegmental ... and acceptance with over 8,000 implantations. ...
Medicine Products:
(Date:12/2/2009)... Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ... dose confirmation and dosimetry trial of Cotara® in patients ... brain cancer. Cotara is a targeted monoclonal antibody ... new treatment for GBM. Cotara specifically targets cells ...
(Date:12/2/2009)... - "Bolstering Biodiversity in Africa: ... Coinciding with the International Year of Biodiversity, ... international conference in Libreville,(Gabon) on the issue of ... attended by government and state leaders, ministers,scientific experts, ...
(Date:12/2/2009)... TechConnect World, an event bringing together the ... cleantech, nanotech, biotech and MEMS, announced the December ... ,, Now in its 14th year, TechConnect World, ... Institute (NSTI), and the Clean Technology and Sustainable ...
(Date:12/2/2009)... Ltd today announced data presentations on its novel oral ... 51st Annual Meeting and Exposition in New Orleans. ,, ... the Phase 1 dose-escalation trial of SB1518 detailing its ... ranging from 100 to 600 mg. These doses were ...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
(Date:12/4/2009)... Inc., developers of the AcceleDent System , ... announced the availability of a new Continuing Education ... leader in professional education for many industries, including ... patient views about orthodontic treatment, a summary of ...
(Date:12/4/2009)... BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" ... that the US Patent and Trademark Office has allowed ... the initial stages of the manufacture of the Company,s ... are key to the very high concentration of dendritic ...
(Date:12/3/2009)... Systems, a subsidiary of Hill-Rom Holdings, Inc. (NYSE: ... new Allen Amatech(TM) OEM (Original Equipment Manufacturer) business website ... reinforces the Allen Amatech(TM) brand identity and includes an ... descriptions and design specifications for the products. "We hope ...
Breaking Medicine Technology:AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Health Robotics Continues its Global Expansion With December 09 ASHPs Launch of Joint Venture in Canada 14954 1Health Robotics Continues its Global Expansion With December 09 ASHPs Launch of Joint Venture in Canada 14954 2Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 6501 1Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 6501 2Orexigen 28R 29 Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635 28c 29 284 29 6498 1Orexigen 28R 29 Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635 28c 29 284 29 6498 2Orexigen 28R 29 Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635 28c 29 284 29 6498 3